Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors-Reference-Cited by-同舟云学术

Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors

Published:2009-02-01 Issue:2 Volume:14 Page:174-180
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Cohen Martin H.¹,Farrell Ann¹,Justice Robert¹,Pazdur Richard¹

Affiliation:

1. Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Abstract

Learning Objectives Identify the appropriate imatinib dose for patients after diagnosis and patients after disease progression. Differentiate between the FDA’s acclerated and regular drug approval processes and their impact on patient care. Demonstrate familiarity with the safety profile of imatinib. This article is available for continuing medical education credit at CME.TheOncologist.com.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2008-0255

Reference12 articles.

1. Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors;Dagher;Clin Cancer Res,2002

2. New guidelines to evaluate the response to treatment in solid tumors;European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;J Natl Cancer Inst,2000

3. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors;Demetri;N Engl J Med,2002

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies;Frontiers in Oncology;2024-07-12

2. The Thin Line between Promiscuous and Privileged Structures in Medicinal Chemistry;Journal of the Brazilian Chemical Society;2024

3. Recent advances in targeted therapy for pancreatic adenocarcinoma;World Journal of Gastrointestinal Oncology;2023-04-15

4. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma;Hepatology;2023-01-03

5. Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer;Frontiers in Molecular Biosciences;2022-12-07